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4-Aminoquinoline-hybridization en route towards
the development of rationally designed antimalarial
agents
Raghu Raj,a Kirkwood M. Landb and Vipan Kumar*a
The resistance of Plasmodium falciparum, the causative agent of malaria, against quinine and chloroquine
along with the lack of malaria vaccines has encouraged the development of various synthetic strategies
towards biologically active scaffolds. An emerging strategy in medicinal chemistry, termed molecular
hybridization, involves the covalent fusion of two or more drugs, active compounds, and/or
pharmacophoric units into a hybrid compound, with fascinating activities and multiple but not essentially
simultaneous pharmacological targets. 4-Aminoquinolines are considered as promising antimalarials and
4-aminoquinoline hybridization is considered as an attractive and feasible approach for the development
of new molecular frameworks for averting and delaying the emergence of drug resistance along with
improved efficacy. The present review article describes the recent developments on the
4-aminoquinoline-hybridization towards the development of new antimalarials.
1. Introduction
In the 20th century, the drug design approach accomplished the
“one-target-one-drug” concept for the discovery of new drugs
which, without any iota of doubt, will be dominant for many
years. According to this concept, a single drug is designed for a
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single target. Although numerous drugs have been designed
and used clinically with good success using this approach, the
strategy of one drug hammering one target remains inadequate
for the treatment of several diseases, such as neurodegenerative
syndromes, cardiovascular diseases, diabetes and cancer, which
involve multiple pathogenic factors.1 Further, an ideal drug for
one target does not always have clinical efficacy due to non-
recognition of the in vivo target or the inability to access the
site of action. This target-based strategy does not always guar-
antee success since some selective drugs can work only in a
selected number of patients. For example, Astra Zeneca's Iressa
(getinib) is designed to treat lung cancer via targeting EGFR
(Epidermal Growth Factor Receptor) protein. The drug provided
an extremely potent response, but only in about 10% of the
infected individuals.2,3 The ineffectiveness of single medicine
paradigm necessitated the discovery of new paradigms where
the drug therapy can block more than one target.
Among the different strategies developed to address the
above issues, combination therapy was considered as a popular
alternative in which a cocktail of drugs is co-administered in the
form of two or more individual tablets to treat unresponsive
patients.4 However, the advantage of combining therapeutic
mechanisms of different drugs through this approach is
compromised by patient compliance.5,6 The multi-component
drug approach, involving co-formulation of two or more drugs
in a single tablet, makes dosing regimens simpler, improves
patient compliance,7,8 and even obviates the risk of drug–drug
interactions present in combination therapy. This strategy has
enhanced research and development (R & D), as evident by the
launch of several multi-component drugs, including Caduet9
(atorvastatin + amlodipine) and Vytorin10 (simvastatin + ezeti-
mibe) for the treatment of cardiovascular disease, Coartem
(artemether + lumefantrine) and Artekin (dihydroartemisinin +
piperaquine) for the treatment of malaria,11 and Atripla12 (efa-
virenz + tenofovir/emtricitabine) against AIDS. However, highly
complex pharmacokinetic (PK)/pharmacodynamic (PD) rela-
tionships in multi-component drugs due to the differences in
relative rates of metabolism of drugs in different patients led to
unpredictable variability. With the failure of these strategies,
the development of new drug molecules that aim to modulate
multiple targets simultaneously (polypharmacology) along with
enhanced efficacy, improved safety, synthetic selectivity and
economic accessibility represents a big challenge for the phar-
maceutical sector.
Nowadays, molecular hybridization has successfully
emerged as a promising tool for medicinal chemists and the
drug design process, in which two or more different pharma-
cophoric units are covalently linked into a single hybrid mole-
cule with superior affinity and efficacy as compared to the
parent drugs.13–16 Molecular hybridization is benecial as
different targets are activated by a single molecule and is
particularly interesting where treatment is limited to a few
commercial drugs or in cases where the discovered bioactive
compounds present high toxicity or pharmacokinetic and
pharmacodynamic limitations.17,18 Hybrid molecules can be
designed in different ways as follows:
Metabolically stable hybrids, in which the desired molecules
are tethered via linkers or spacers, which may or may not be
stable under in vivo conditions. These conjugates interact
preferably at more than one target with effects mostly additive
or synergistic for a particular disease.
 Cleavable molecular hybrids, which get metabolized in vivo
with the release of parent drug molecules and have different
targets and mechanisms of action.
 Molecular hybrids can also be prepared via either fusing
the drug molecules without introducing a linker or by merging
the individual molecules by taking advantage of commonalities
in their structure.
Today, much of the world's population is affected by infec-
tious diseases that remain instrumental in debilitating poverty.
According to the latest statistics published in 2012, 8.7 million
people died worldwide in 2008 due to infectious diseases.19
People who lack food, shelter, security and social protection are
more vulnerable to infectious diseases since they oen lack the
most basic measures of prevention and care. Pathogenic
microorganisms, including bacteria, viruses, parasites or fungi,
are themajor cause of infectious disease and can spread directly
or indirectly, from person to person. Among infectious diseases,
malaria, tuberculosis (TB) and HIV/AIDS are high on the global
agenda while other less important infections include Chagas
disease, human African trypanosomiasis, trichomoniasis and
leishmaniasis.20
Malaria is considered to be one of the most dangerous
parasitic diseases because of its high morbidity and mortality,
as well as its socio-economic impacts on the malaria-endemic
region. It remains a chief cause of illness and death in trop-
ical and subtropical countries, including Africa, Asia and South
America. Approximately 90 percent cases of malaria are found
in sub-Saharan Africa. According to the World Health Organi-
zation (WHO) report 2012, 3.4 billion people in 103 countries
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are at risk of infection with 207 million malaria cases and
627 000 deaths, with the majority of victims being pregnant
women or children less than the age of ve years.21 The disease
is caused by genus Plasmodium and, among 200 Plasmodium
species, only ve infect humans, viz. Plasmodium falciparum,
P. vivax, P. ovale, P. malariae and P. knowlesi, with P. falciparum
being the most virulent. Historically, the safe and cheap drug
chloroquine (CQ) was extensively used for the treatment of
malaria due to its excellent clinical efficacy, restricted host
toxicity and simple cost-effective synthesis. CQ is believed to
target ferriprotoporphyrin IX (FPIX) heme inside the digestive
vacuole (DV) of the parasite. FPIX, being toxic to the parasite in
its free state, is sequestered as a non-toxic crystalline hemozoin,
also called “malarial pigment.” CQ forms a complex with FPIX,
resulting in the accumulation of toxic hematin (Fe(III)PPIX)
within the digestive vacuole and instigating the death of the
parasite.22–29 However, the onset of resistant strains to the
available antimalarial drugs, including CQ, is responsible for
the global rise of malaria and offers a strong impetus for the
development of new antimalarial drugs.30,31 The development of
resistance of P. falciparum to CQ is mainly attributed to the
mutations in the P. falciparum chloroquine resistant transporter
gene (PfCRT), a protein involved in the efflux of drug and proton
equilibrium across the membrane of the digestive vacuole,
resulting in poor accumulation of CQ in the acidic food vacuole
of the parasite.32,33 Currently, the WHO recommends artemisi-
nin based combination therapy (ACT) comprising artemisinin
and its semi-synthetic derivatives in combination with existing
drugs for the treatment of malaria. This drug regimen is
considered successful against both CQ-sensitive as well as
CQ-resistant strains of malaria.34–36 However, recent reports of
the development of clinical resistance to ACT in Southeast Asia
threaten this combination therapy.37
4-Aminoquinoline hybridization is now considered an
attractive and viable strategy for preventing and delaying the
emergence of drug resistance along with the improvement in
efficacy.38–42 The success of the quinoline-hybridization strategy
was exemplied by several potential antimalarials, such as tri-
oxaferroquines,43 trioxaquines,44 artemisinin–quinine hybrid,45
4-aminoquinoline based tetraoxanes,46 clotrimazole-based-
4-aminoquinoline47 and isatin–4-aminoquinoline hybrids.48
The present review article encompasses the recent develop-
ments on the utility of 4-aminoquinoline-hybridization towards
the development of novel antimalarials. A special focus has
been given to the structure–activity relationship, IC50 values
against CQ-sensitive and resistant strains, in vivo evaluation
data and cytotoxic studies of the promising candidates that
have emerged from this strategy.
2. 4-Aminoquinoline-based
antimalarial conjugates
2.1 4-Aminoquinoline–chalcone conjugates
Chalcones and dienones are structurally linked compounds
that have been revealed to exhibit notable in vitro and in vivo
antimalarial activity49–52 by acting as inhibitors of either
plasmodial aspartate proteases,53 cysteine proteases54 or
permeability pathways initiated into erythrocyte cell
membranes by the malaria parasite.55 Chibale and co-workers
applied the molecular hybridization strategy via Cu(I)-cata-
lyzed cycloaddition reaction of terminal alkynes and azides for
the synthesis of series of 1H-1,2,3-triazole linked chalcone and
dienone conjugates containing aminoquinoline and nucleoside
templates (Fig. 1).56 The synthesized hybrids were screened for
their antimalarial activity against the CQ-sensitive (D10) and
CQ-resistant (Dd2 and W2) strains of P. falciparum. Notably, the
azidothymidine (AZT) conjugates with both chalcones and
dienones did not show any improvement in the antimalarial
activity over their acetylenic precursors while retention of
activity was observed in most cases. The quinoline-
hybridization approach led to the identication of highly
Fig. 1 General structures for triazole-linked chalcone and dienone
hybrid compounds comprising AZT and aminoquinoline with the most
active hybrid being 4a.
Scheme 1 Reagents and conditions: (a) ethanol, rt, 10 min.
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potent hybrids, with the most active conjugate 4a having sub-
micromolar IC50 values of 0.04, 0.07 and 0.09 mM against
tested D10, Dd2 and W2 strains of P. falciparum, respectively.
Cytotoxicity against the Chinese Hamster Ovarian cell line was
determined and the hybrid 4a proved to be non-cytotoxic even at
the highest concentration tested (100 mM).
Sashidhara and co-workers utilized an uncommon approach
towards the synthesis of keto-enamine tethered chalcone–
4-aminoquinoline conjugates (9).57 The synthesized conjugates
were evaluated for their antimalarial potential against a
CQ-sensitive (3D7) strain of P. falciparum (Scheme 1). The
promising compounds from in vitro assay were further screened
for their antimalarial efficacy against P. yoelii (CQ-resistant N-67
strain) in Swiss mice. Two of the synthesized conjugates dis-
played suppression of 99.9 percent parasitemia on day 4.
Mechanistically, the test compounds exhibited an antimalarial
mode of action similar to that of CQ, as conrmed by inhibition
of b-hematin formation studies.
The above work was further extended towards the synthesis
of 4-aminoquinoline–chalcone conjugates by following the
sequence of synthetic steps shown in Scheme 2 along with their
antimalarial evaluation.58 Most of the synthesized conjugates
showed improved antimalarial prole against the Q-resistant
K1 strain when compared to CQ. Structure activity relation-
ship (SAR) studies demonstrated the dependence of the activity
prole on the substitution pattern as well as the number of
substituents present on the phenyl ring. The presence of elec-
tron releasing groups (R ¼ –CH3, –OCH3) has been shown to
improve the activity proles while replacing them with electron
withdrawing groups (R ¼ –Cl, –NO2) reduced the antimalarial
activity, with the exception of uorine. b-Hematin studies were
also carried out for the synthesized conjugates with the three
compounds being most active in inhibition of b-hematin
formation with IC50 values of 3.46, 3.52 and 3.74 mg ml
1.
Insuasty et al. utilized 7-chloroquinoline–amino-chalcone
hybrids (16) for the preparation of a series of N-acetyl and
N-formyl-pyrazoline derivatives (17 and 18) in acceptable to
good yields via a cyclo-condensation reaction using hydrazine
hydrate under acidic conditions (Scheme 3). The synthesized
conjugates were bio-evaluated for their antimalarial and anti-
cancer proles.59 The anticancer proles against 60 cell lines
revealed that GI50 values for most of these conjugates range
from 0.13 to 0.99 mM. The antimalarial activity performed
against the NF54 strain of P. falciparum revealed that one of the
N-formyl-pyrazoline derivatives, 18a, exhibited 50.8%
inhibition.
A series of 4-aminoquinolinyl-chalcone amides (21) were
synthesized by N'Da through condensation of carboxylic acid-
functionalized chalcone with aminoquinolines (Scheme 4)
along with their screening against CQ-sensitive (3D7) and
CQ-resistant (W2) strains of P. falciparum. Cytotoxicity against
the WI-38 cell line of normal human fetal lung broblast was
also evaluated.60 The IC50 values of the synthesized conjugates
ranged between 0.04–0.5 mM and 0.07–1.8 mM against 3D7 and
W2, respectively. SAR studies revealed the increased antima-
larial activity of the amides with the increase in lipophilicity and
alkyl chain length. Moderate to high toxicity towards mamma-
lian cells was observed for these conjugates. The most active
compound featuring 1,6-diaminohexane as the linker was two-
fold more potent than CQ against the 3D7 and W2 strains
despite its predicted high lipophilicity, low solubility and poor
absorption properties.
2.2 4-Aminoquinoline–pyrimidine conjugates
Rawat and co-workers reported the preparation of a library of
4-aminoquinoline–pyrimidine conjugates in an attempt to
Scheme 2 Reagents and conditions: (a) hydrazine hydrate, EtOH,
reflux, 8 h; (b) 4-hydroxybenzaldehyde, EtOH, reflux, 2–3 h; (c)
4-chlorophenacyl bromide, K2CO3, acetonitrile, rt, 2 h; (d) different
substituted aldehydes, 10% methanolic KOH, rt.
Scheme 3 Reagents and conditions: (a) KOH, MeOH, rt; (b) hydrazine
hydrate, acetic acid, reflux; (c) hydrazine hydrate, formic acid, DMF,
reflux.
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search for more active molecules with effectiveness against both
CQ-sensitive and CQ-resistant strains of P. falciparum.61 Among
the synthesized compounds, eleven conjugates displayed
enhanced antimalarial activity compared to CQ against both D6
and W2 strains, while four conjugates (22, 23, 24, and 25, Fig. 2)
showed better activity against both CQ-sensitive as well as
CQ-resistant (D6 andW2) strains of P. falciparum in comparison
to pyrimethamine. Most of the conjugates were found to be non-
cytotoxic up to a concentration of 60 mM, while others showed
mild toxicities. Most of the conjugates exhibited a high selective
index; compounds 22 and 25, with IC50 values of 0.005 and
0.006 mM, respectively, against the D6 strain and 0.03 and 0.06
mM, respectively, against the W2 strain of P. falciparum, were
selected for in vivo studies, and showed outstanding activity in a
mouse model of P. berghei without any toxicity.
In a recent communication, Singh and co-workers showed
the synthesis of molecular conjugates 27 based on 7-chloro-4-
aminoquinoline (7) and 2-aminopyrimidine (26) motifs, as
shown in Scheme 5.62 The rationale behind using 2-amino-
pyrimidine was because of its well established antimalarial
potential, as evidenced by the structurally related drug pyri-
methamine. The antiplasmodial proles of the synthesized
conjugates were in the nanomolar range, with the most potent
hybrid exhibiting an IC50 value of 3.6 nM, 56-fold less compared
to CQ against the CQ-resistant K1 strain. Almost all of the
synthesized compounds were cytotoxic and the binding studies
with DNA implied their strong affinity for target parasite type AT
rich pUC18 DNA. The active conjugates also showed good
inhibitory activity for b-haematin formation, suggestive of the
fact that the observed antiplasmodial potential of the conju-
gates in the present case is because of their ability to act on
multiple targets.
A range of 7-chloroquinoline–pyrimidine hybrids, viz. 30 and
31, were synthesized by N'Da and co-workers via aromatic
nucleophilic substitution reaction of 4-aminoquinolines with
2,6-diamino-4-chloropyrimidine and their antiplasmodial
potential evaluated. The conjugates were evaluated alongside
CQ, pyrimethamine (PM) and their xed combinations viz.
CQ/PM (1 : 1) and CQ/PM (1 : 4) against the CQ-susceptible D10
and -resistant Dd2 strain of P. falciparum (Scheme 6).63 The
cytotoxic proles of the synthesized scaffolds were also evalu-
ated against the Chinese Hamster Ovarian (CHO) cell line. All
the synthesized hybrids showed activity against both D10 and
Dd2 strains with good selective index. The most potent
compound of the series 30 with piperazine as the linker showed
comparable activity to that of PM and CQ against the D10 strain
(IC50 ¼ 0.07 mM) while a three-fold better potency than that for
CQ against Dd2 strain (IC50 ¼ 0.157 mM) was observed.
Further, a library of piperazine tethered 4-aminoquinoline–
pyrimidine conjugates was prepared and screened for their
antimalarial proles over CQ-sensitive (D6) and CQ-resistant
(W2) strains of P. falciparum while cytotoxicity was evaluated
against the mammalian Vero cell line.64 Nine conjugates were
shown to have superior antimalarial potency against both the
Scheme 4 Reagents and conditions: (a) CDI, DCM : DMF, rt, 24 h.
Fig. 2 Most potent 4-aminoquinoline–pyrimidine conjugates 22, 23,
24 and 25.
Scheme 5 Reagents and conditions: (a) K2CO3, THF, 48 h, rt.
Scheme 6 Reagents and conditions: (a) piperazine, DMF, 80–135 C,
5 h; (b) diaminoalkane/aryldiamine, neat or DMF, 80–150 C, 24 h; (c)
aminoalcohol, neat, 120 C, 24 h; (d) NaH, DMF, rt, 1 h; (e) 2,6-dia-
mino-4-chloropyrimidine, DMF, 135 C, 16–24 h.
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strains with IC50 values ranging from 0.13 to 0.14 mM. Out of
these, compound 32 (Fig. 3) proved to be the most potent
among the synthesized conjugates and its antimalarial activity
was found to be 2.5 fold more than that of the standard drug
CQ. All the synthesized conjugates were non-cytotoxic against
the Vero cell line.
The above work was further extended for the preparation of
4-aminoquinoline–pyrimidine hybrids 34, as shown in Scheme
7. All the synthesized compounds were screened for their anti-
plasmodial activity against D6 and W2 strains of P. falciparum,
depicting activity in the nano-molar range.65 Numerous
compounds were found to be nontoxic to the mammalian cell
lines and showed promising in vitro antimalarial activity over
both CQ-sensitive and -resistant strains with high values of
selective index. The most potent conjugate 34a with an IC50
value of 0.033 and 0.058 mM against D6 and W2 strains of
P. falciparum, respectively, was chosen for in vivo studies and
exhibited signicant suppression of parasitemia. The heme
binding studies conrmed heme as one of the possible targets
of these hybrids with heme forming a stable 1 : 1 complex with
these conjugates. Potent compounds from in vitro antimalarial
activity data were selected for molecular docking simulations
and showed good interaction with the binding sites of PfDHFR.
2.3 4-Aminoquinoline–triazine conjugates
Rawat et al. described the synthesis of a library of
4-aminoquinoline-1,2,3-triazoles (36) and 4-aminoquinoline-
1,2,3-triazole–1,3,5-triazine conjugates (38) by utilizing Huisgen-
1,3-dipolar cycloaddition reaction of 4-azido-7-chloroquinoline
with variedly substituted terminal alkynes (Scheme 8).66 It has
been hypothesized that amalgamation of a basic nucleus viz.
triazine with 4-aminoquinoline would enhance the accumula-
tion of the conjugate in the digestive food vacuole, targeting
P. falciparum dihydrofolate reductase (PfDHFR). However, the
antimalarial prole of the synthesized conjugates against
CQ-sensitive D6 and CQ-resistant W2 strains revealed that none
of the hybrids exhibited better activity than that of CQ.
The above study was further extended by Chauhan and
co-workers in the synthesis of 4-anilinoquinoline-triazine
derivatives (40 and 41) using readily available and cheap start-
ing materials (Scheme 9). The compounds were assessed for
their antiplasmodial efficacy against theCQ-sensitive 3D7 strain
of P. falciparum as well as for their cytotoxicity towards the
mammalian Vero cell line.67 The most promising and non-
cytotoxic compounds from the preliminary studies were
chosen for in vivo screening in Swiss mice infected with the
Fig. 3 Most potent piperazine tethered 4-aminoquinoline–pyrimidine
conjugate 32 and CQ.
Scheme 7 Reagents and conditions: (a) TEA, EtOH, rt, overnight; (b)
K2CO3, NMP, 140–150 C, 10–12 h.
Scheme 8 Reagents and conditions: (a) CuSO4$5H2O, sodium
ascorbate, t-BuOH : H2O (1 : 1), 40 C, 3 h.
Scheme 9 Reagents and conditions: (a) mono-substituted triazines,
THF, reflux, 8 h; (b) various amines, THF, reflux, 5 h.
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CQ-resistant N-64 strain of P. yoelli. These studies resulted in
the identication of two orally active compounds with piperi-
dine functionality. The results obtained are suggestive of the
fact that the antimalarial activity in these conjugates can be
attributed to the metabolic stability of piperidine functionality.
The selected conjugates were further investigated for their
ability to inhibit b-hematin formation. All the tested hybrids
exhibited better inhibitory activities of b-haematin formation
(IC50 ranging from 2.65 to 3.16 mM) than CQ (IC50 ¼ 3.65 mM),
which revealed that, apart from targeting heme, there might be
the possibility of other mechanisms of action.
The use of triazine functionality for the synthesis of molec-
ular conjugates with antimalarial potential was further elabo-
rated by Bhat and co-workers in the synthesis of variedly
functionalized 1,2,3-triazine–4-aminoquinoline conjugates (46)
attached via thiourea functionality as the linker (Scheme 10).
The determination of their antimalarial efficacy was done
against the CQ-sensitive (3D7) and CQ-resistant (RKL-2) strains
of P. falciparum.68 The observed SAR revealed a preference for
electron withdrawing substituents, viz. bromo and hydroxyl
groups, while the presence of electron donating substituents,
including methyl and methoxy, adversely affected the activity
proles. The observed activities were further substantiated by
docking simulations performed by using the ligand t module
within Discovery Studio 2.5 on wild and quadruple mutant
strains of P. falciparum dihydrofolate reductase thymidylate
synthase (pf-DHFR-TS).
Further extension of the above work resulted in the synthesis
of 4-aminoquinoline–1,3,5-triazine derivatives (49) connected
through non-ionizable covalent linkers (Scheme 11).69 The anti-
plasmodial prole again showed a similar SAR to that observed
earlier with a marked preference for electron withdrawing
substituents for good activity. Further, addition of basic moie-
ties, such asmorpholine, piperidine and 1,3-diaminopropane, in
the synthesized conjugates was shown to enhance the antima-
larial activity. The evaluation results were correlated using
docking studies carried out on wild and quadruple mutants
pf-DHFR-TS. In the wild type strain, most of the hybrids revealed
a hydrophobic interaction between the phenyl ring of conjugates
with the Phe58 residue as well as a s–p interaction between the
1,3,5-triazine ring and the Leu46 residue. Similarly, a hydro-
phobic interaction was observed between the phenyl ring and
Phe58 in addition to H-bond formation between the 1,3,5-
triazine ring and Ser111 in the quadruple mutant of pf-DHFR-TS.
Further, it was observed that the quinoline moiety was engaged
in the formation of a p interaction with Arg59.
2.4 4-Aminoquinoline–thiazolidine conjugates
An alternative pathway for obtaining new and promising anti-
malarial compounds was disclosed by Kouznetsov and
co-workers. A library of 21 heterocyclic scaffolds consisting of
either N-(aminoalkyl)thiazolidin-4-one-4-aminoquinoline conju-
gates (50) or substituted N-benzylamino-7-chloroquinolines (51)
was prepared by following the sequence of steps depicted in
Scheme 12.70 The antimalarial evaluation against 3D7 and Dd2
strains showed that four of the N-benzylamino-7-
chloroquinoline derivatives (51) are up to 3-fold more active
compared to the standard drug, CQ. Non-specic cytotoxicity
assay on J774 murine macrophages and HepG2 cells (human
hepatocellular carcinoma cell line) proved their high selectivity
index and hence the potential for in vivo evaluation.
Chauhan and co-workers recently explored the synthesis of 4-
aminoquinoline–rhodanine hybrids along with their in vitro
Scheme 10 Reagents and conditions: (a) reflux with stirring for 18 h at
90–120 C; (b) dry acetone, 0–5 C, 1 h, then 40–45 C for a further
3 h; (c) piperazine, 1,4-dioxane, 120–130 C, 5–6 h; (d) dry acetone,
40–45 C, 18 h.
Scheme 11 Reagents and conditions: (a) reflux 1 h at 80 C followed
by 6–8 h at 120–130 C; (b) 1,4-dioxane 0–5 C, 1 h, 40–45 C, 3 h; (c)
1,4-dioxane, 120–130 C, 6–7 h.
Scheme 12 Reagents and conditions: (a) diaminoalkane, 80 C for 1 h,
140–150 C for 6–7 h; (b) ArCHO, HSCH2COOH, PhMe, 4–5 h reflux;
(c) substituted N-benzylamine, K2CO3, DMF, 140 C, 10 h.
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antimalarial efficacy against K1 and 3D7 strains of P. falciparum, as
well as their cytotoxicity against the Vero cell line (Scheme 13).71
Although none of the hybrids was more potent than CQ against
the 3D7 strain, four of the tested conjugates showed antimalarial
activity comparable to CQ with IC50 values in the range of 13.2–
45.5 nMagainst K1 strain alongwith high selectivity. Furthermore,
some of the hybrids were also tested for their anti-mycobacterial
potential against the H37Rv strain of M. tuberculosis with three of
the potent compounds exhibiting minimum inhibitory concen-
tration (MIC) values of 6.25 mM. In addition, inhibition of b-
hematin formation studies disclosed that the test conjugates were
more active than CQ in the inhibition of hemozoin formation,
clearly validating their mechanism of action.
A series of differently substituted 4-aminoquinolines having
thiazolidin-4-ones (54), [1,3]thiazinan-4-ones (55) or 2,3-dihy-
drobenzo[e][1,3]thiazin-4-ones (56) at the terminal amino
functionality was synthesized via a three-component reaction
between 4-aminoquinolines, aryl aldehydes and appropriate
mercapto acids (Scheme 14).72 Among the compounds tested
against the NF-54 strain of P. falciparum, nine showed IC50
values ranging between 0.013–0.98 mM. The promising
compounds from in vitro assay were further selected for in vivo
activity testing in Swiss mice using N-67 strain of P. yoelli. The
most potent compound from in vivo analysis suppressed para-
sitemia by 81 percent on day 4 compared to 100 percent
suppression exhibited by CQ. SAR studies showed that the
lateral side chain modication of 4-aminoquinoline in these
conjugates was well tolerated with the best results obtained
with a two- or three-carbon chain as the linker. The biochemical
studies conrmed their association with hematin and hence
conrmed the mechanism of action of the test compounds.
2.5 4-Aminoquinoline–clotrimazole conjugates
With the aim of developing new antimalarials, in a recent
communication Gemma and co-workers identied a new poly-
aromatic antimalarial pharmacophore based on a clotrimazole
scaffold.73 Clotrimazole is a popular antimycotic drug with weak
antimalarial activity (IC50 ¼ 0.55 mM) against the W2 strain of
P. falciparum. However, its peculiar structural features, viz. (i)
the presence of an imidazole nucleus, identied to mediate
electron transfer reaction and (ii) the triphenylmethyl system
known to stabilize radical intermediate, makes it an ideal
candidate to interact with the haemoglobin-derived ferro-
protoporphyrin (Fe(II)–FP) complex in the food vacuole of the
parasite. Consequently, a number of polyaromatic pharmaco-
phores structurally related to clotrimazole have been synthe-
sized with an extension towards clotrimazole–4–
aminoquinoline conjugates. The antimalarial evaluation of the
synthesized scaffolds showed dependence upon some key
structural features, viz. (i) the protonatable side chain, (ii) the
imidazole ring, and (iii) the aryl/heteroaryl system. The most
promising compounds (57, 58 and 59 in Fig. 4) were further
evaluated to assess their in vivo efficacy against P. chabaudi in
CDI mice aer oral administration in a 4 day suppression test.
The results showed that compounds 57 and 58 have low
propensity to produce rapid resistance along with in vivo activity
against plasmodia and oral bioavailability.
The above protocol was further extended towards the
synthesis of a series of antimalarial hybrids by combining the
4-aminoquinoline unit with that of clotrimazole, as depicted in
Fig. 5.74 The antimalarial studies were carried out in vitro
against CQ-sensitive and -resistant strains as well as in vivo in a
rodent malaria model. Compounds 63 and 64 displayed strong
antimalarial activity against P. berghei aer oral administration.
The compounds have been shown to interfere with the process
of heme detoxication, as conrmed by BHIA assay. Cytotox-
icity, genotoxic potential and effects on cardiac function of lead
compounds were also assessed with the compound 63 emerging
as a good hit because of its promising antimalarial potency and
an optimal half-life in mice.
2.6 4-Aminoquinoline–azithromycin conjugates
Azithromycin, a semi-synthetic macrolide antibiotic, was
recently discovered as a slow acting antimalarial75,76 that wields
its activity via inhibiting protein synthesis on prokaryote-like
ribosomes in P. organelle.77 Currently, it is in clinical trials
and has been used as a combination partner with different
Scheme 13 Reagents and conditions: (a) CS2, BrCH2COOC2H5,
acetonitrile, rt, 3–5 h, (b) acetic acid, ammonium acetate, aromatic/
heteroaromatic aldehydes, 90 C, 4–6 h.
Scheme 14 Reagents and conditions: (a) DCC, THF, rt or PhMe, reflux. Fig. 4 Most potent compounds 57, 58 and 59.
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antimalarials. Peric´ and collaborators employed a molecular
hybridization strategy for the synthesis of azithromycin–quin-
oline antimalarial conjugates.78 Forty two new azithromycin
analogues and azithromycin–quinoline conjugates with amide
and amine functionalities were synthesized using simple and
economical chemical procedures. These scaffolds displayed
100-fold improvement in in vitro potency with high selectivity,
pharmacokinetics (PK) and in vivo efficacy over azithromycin
against the P. falciparum TM91C235 strain, a multidrug resis-
tant clone from Southeast Asia. The screening of the promising
compounds in a mouse efficacy model resulted in the identi-
cation of ve scaffolds, viz. three amine (65, 66, 67) and two
amide (68, 69) derivatives, exhibiting better in vivo efficacy
compared to azithromycin (Fig. 6). The most potent of the
tested compounds 65 (Fig. 6) showed 100-fold better in vitro
activity with excellent pharmacokinetic parameters curing mice
more efficiently than azithromycin.
Peric et al. further extended this concept towards the devel-
opment of the azalide class of antimalarials via synthesis of 20-o-
substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
derivatives covalently linked to varied substituted quinolines at
position 20, as depicted in Fig. 7.79 Antimalarial proles of the
test conjugates against the CQ-sensitive 3D7 strain showed
100-fold improvement over azithromycin while 48-fold
enhancement was observed against the CQ-resistant W2 strain
of P. falciparum. These results have facilitated these macrolides
for the preclinical development of malaria-specic agents.
2.7 4-Aminoquinoline–b-lactam conjugates
A series of 1H-1,2,3-triazole-linked 7-chloroquinoline–b-lactam
conjugates (72 and 73) was synthesized by Kumar and
co-workers utilizing click chemistry, as shown in Fig. 8. The
antimalarial potency of the synthesized conjugates against a
W2-resistant strain of P. falciparum was found to be dependent
on the substituent present at the N-1 position of the b-lactam
ring and the presence of bis-triazole at C-3 position. The
observed antimalarial efficacy was further validated by docking
studies through inhibition of P. falciparum dihydrofolate
reductase (PfDHFR).80
On the basis of these preliminary results, Kumar et al.
further extended their work on 4-aminoquinoline hybridization
by synthesizing 4-aminoquinoline–b-lactam conjugates linked
via a diverse range of linkers, viz. amide81 (75, Fig. 8) and non-
ionizable covalent bonds (74, Fig. 8),81 urea82 (76, Fig. 8) and
oxalamide82 (77, Fig. 8) functionalities along with well-
modulated alkyl chain lengths. All the synthesized conjugates
were screened for their antimalarial potential against a W2
resistant strain of P. falciparum. Antiplasmodial data revealed
that the activity depends on the nature of the linker, the alkyl
chain length and the substituent present at the N-1 position of
the b-lactam ring. On comparing the potencies among the
amide and alkyl chain tethered series, the conjugates linked via
non-ionizable covalent alkyl chain linker proved to be better in
inhibiting the growth of P. falciparum while the introduction of
amide functionality adversely affected the activity proles. The
introduction of urea/oxalamide functionalities, on the other
hand, resulted in improvement of the antiplasmodial proles.
Themost potent and non-cytotoxic conjugate (77a, Fig. 8) among
the 7-chloroquinoline–b-lactam series with the best
Fig. 6 Structure of azithromycin and potent azalide hybrids used for in
vivo study in the mouse model.
Fig. 7 General structure of hybrids of 20-O-substituted-9-deoxo-9a-
methyl-9a-aza-9a-homoerythromycin A and quinolone.
Fig. 5 Molecular conjugates 60, 61 and 62 of 4-aminoquinoline and
clotrimazole along with their potent precursors 63 and 64.
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combination of N-cyclohexyl substituent at N-1, alkyl chain
length (n ¼ 6) and oxalamide functionality exhibited an IC50 of
39.9 nM.
Further, Kumar et al. synthesized a library of C-3 thiourea
tethered b-lactam–7-chloroquinoline conjugates (78) along with
the unexpectedly formed 7-chloroquinoline–thiohydantoin
derivatives (79) with the aim of searching antimalarial struc-
ture–activity relationships (Fig. 9). The synthesized thiourea-
tethered 7-chloroquinoline–b-lactam conjugates 78 were
found to be ineffective in inhibiting the growth of P. falciparum.
However, the unexpected formed product viz. 7-chloroquino-
line–thiohydantoins 79 demonstrated nanomolar antimalarial
activities against the W2 strain of cultured P. falciparum, with
themost potent and non-cytotoxic compound exhibiting an IC50
of 39.8 nM. b-Hematin formation studies strongly supported
the mechanism of their action via the inhibition of b-hematin
formation having IC50 values comparable to those of CQ.83
2.8 4-Aminoquinoline–isatin conjugates
Santos and colleagues designed, synthesized and evaluated
3-methylene-substituted indolinones (Fig. 10, 80–85) as
falcipain inhibitors and antiplasmodial agents.84 Various
indolinones with a Leu-i-amyl recognitionmoiety were shown to
display fair inhibitory activity of P. falciparum cysteine protease
falcipain-2 and antimalarial potency against the W2 strain of
P. falciparum in the low mM range. Importantly, compounds
lacking the recognition moiety were devoid of FP-2 inhibition
and interaction of the Leu-i-amyl sequence with the S2 pocket.
Further, the introduction of a 4-aminoquinoline to the C-3
position of the indolinone-2-one scaffold (85) led to a consid-
erable enhancement in the antiplasmodial activity, suggestive
of the fact that the 3-methylene-indolinone-2-ones could
become forthcoming lead compounds for the development of
new antimalarials.
Kumar et al. synthesized a library of isatin–7-chloroquino-
line conjugates linked by 1H-1,2,3-triazole moiety along with
assessment of their antiplasmodial proles (Scheme 15). The
tested compounds (88) were devoid of antiplasmodial activity,
while 89, having an alkyl chain between isatin and 7-chloro-
quinoline moieties, displayed enhancement in antiplasmodial
potency. Activity was found to depend on the C-5 substituent of
the isatin ring and on the alkyl chain length between the isatin
and 7-chloroquinoline moieties. The most potent conjugate,
Fig. 8 b-Lactam–4-amino-quinoline conjugates.
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with the best combination of propyl linker (n ¼ 3) and chloro-
substituent at the C-5 position of isatin ring, exhibited an IC50
value of 1.21 mM.85
The above work was further extended towards the synthesis
of triazole linked isatin–7-chloroquinoline (93) and 3-hydroxy-
indole–7-chloroquinoline hybrids (94) by following the
synthetic protocol shown in Fig. 11 along with their anti-
plasmodial evaluation against the CQ-resistant W2 strain.86
studies revealed the dependence of activities on the length of
alkyl chain but independent of the nature of the substituent
present at the C-5 position of the isatin or indole ring. Most of
the conjugates were less active than the standard drug CQ;
however, the best conjugate with an optimum combination of
3-hydroxy-indole ring and n-butyl linker exhibited an IC50 value
of 69 nM, comparable to that of CQ. Further, Kumar and
co-workers synthesized piperazine tethered 7-chloroquinoline–
isatin conjugates (95 and 96, Fig. 12) by both direct nucleophilic
substitution and Cu(I)Cl mediated Mannich reaction.87 All the
synthesized conjugates were assessed for their anti-plasmodial,
anti-tubercular and cytotoxic evaluation. Analysis of anti-
plasmodial activity data against the W2 strain showed that
none of conjugates were as active as CQ, although some
conjugates proved to have good anti-malarial efficacy with IC50s
ranging from 0.22 to 0.27 mM.
Anti-tubercular evaluation against M. tuberculosis revealed
the dependence of the activity prole on the presence of a
substituent at the C-5 position of the isatin ring whereas longer
alkyl chain lengths badly affected the efficacy of the
compounds. Compound 95, with a uoro substituent, was
shown to have good anti-TB efficacy with six times more potency
than the standard drug, Cephalexin. On the other hand, Man-
nich adducts (96) were found to be ineffective in inhibiting the
growth of M. tuberculosis. The most potent compound 95a
(Fig. 12), with an IC50 of 0.22 mM against the CQ-resistant strain
of P. falciparum and 31.62 mMagainst the 3T6 cell line, exhibited
a high selectivity index.
Recently, Kumar et al. synthesized b-amino alcohol tethered
isatin–4-aminoquinoline conjugates with the aim of investi-
gating their antimalarial structure activity relationship. SAR
studies have shown a clear preference for shorter alkyl chain
lengths (n¼ 2, 3) and the presence of a Cl-substituent at the C-5
position of the isatin ring for good activity. The two most potent
and non-cytotoxic conjugates (97 and 98, Fig. 13) displayed
antiplasmodial potency comparable to that of CQ, with IC50
values of 11.7 and 13.5 nM, against the W2 resistant strain of
P. falciparum.88
2.9 Organometallic based 4-aminoquinoline conjugates
Over the past few years, bio-organometallic chemistry has
emerged as a quickly growing and maturing area that associates
organometallic chemistry to medicine, biology and molecular
biotechnology.89 The replacement of organic ligands with metal
complexes has the ability to enhance the activity of biological
compounds along with potential advantages, such as the
synthesis of stable metal complexes with predictable structures,
the capability to tune ligand affinities in accordance with their
electron transfer properties, substitution rates and reduction
potentials along with effective biological targeting.90 Among the
implausible number and variety of roles that metals play in
current medicine, cancer91 and malaria92 treatments are
appreciated as possibly the most important application of
metal-based drugs.
In malaria chemotherapy, resistance to established drugs
may be overcome by bio-organometallics through new metal
specic modes of action. Ferroquine (99, FQ, SSR97193, Fig. 14),
the ferrocene analogue of CQ, is themost pertinent example of a
bio-organometallic compound that showed higher antimalarial
Fig. 10 General structures of synthesized 3-methylene-substituted
indolinone analogues 80–85.
Scheme 15 Reagents and conditions: (a) CuSO4, sodium ascorbate,
EtOH : H2O, rt 7 h.
Fig. 9 General structures of b-lactam–7-chloroquinoline conjugates
(78) and 7-chloroquinoline–thiohydantoin derivatives (79).
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potency in vivo on mice infected with P. yoelii NS and P. berghei
N. It is twenty two times more active against schizontocides
than CQ against the CQ-resistant strain of P. falciparum. The
effectiveness of FQ against the CQ-resistant strain could
possibly be due to its capability to penetrate in the infected
cells.93
Biot et al. further utilized the ferroquine pharmacophore as a
template for the design of two novel series of ferrocenic anti-
malarial conjugates comprising FQ derivatives hybridized with
a glutathione reductase inhibitor (or glutathione depletor) via
an appropriate cleavable amide bond (Scheme 16). In vitro
antimalarial studies on CQ-susceptible (NF54) and CQ-resistant
(K1) strains were conducted, with emphasis on the study of their
mechanism of action.94 Among the series of synthesized
conjugates, the compounds 101a–101f were found to exhibit the
most potent in vitro activity with IC50 values in the nanomolar
range. However, their antiplasmodial activity was slightly less
than the precursor FQs 100a–100f possibly due to the cleavage
of the amide bond and the oxidative metabolism of the side
chain of the FQ in the digestive vacuole of the parasite. The
observed antiplasmodial activity of FQ was mainly attributed to
the high potential of the ferrocene core exhibiting a redox
mechanism different from the mechanism of action of
chloroquine.
The discovery of ferroquine (99, FQ, SSR97193) as a prom-
ising antimalarial prompted the synthesis of corresponding
rhenium organometallics to measure the signicance of the
ferrocenyl group (Scheme 17).95 All the synthesized compounds
(organic along with their organometallic counterparts) were
assessed for their in vitro antiplasmodial potency against the
CQ-resistant (W2) and the CQ-susceptible (3D7) strains of
P. falciparum. The cyrhetrene conjugates (105 and 106),
however, were found to be less active than the corresponding
ferrocene and organic analogues.
Orvig et al. explored the synthesis of CQ-bridged ferroceno-
phane analogues of ferroquine in which the terminal nitrogen
Fig. 11 General structures of target hybrid compounds.
Fig. 12 General structures of piperazine tethered 7-chloroquinoline–
isatin conjugates 95 and 96 along with most potent conjugate 95a.
Fig. 13 The two most potent b-amino alcohol tethered isatin–4-
aminoquinoline conjugates 97 and 98.
Fig. 14 Structure of ferroquine (FQ), 99. Scheme 16 Reagents and conditions: (a) EDCI, DCM, rt.
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of the CQ derivative bridged the two cyclopentadienyl rings of
ferrocene (110a–110e) alongside their mono-substituted ferro-
cene analogues (109a–109e) and organic fragments (108a–108e)
(Fig. 15).96 All the synthesized compounds were screened for
their antiplasmodial potency and were found to be active over
both CQ-sensitive and -resistant strains. Mono-substituted fer-
rocenyl analogues were found to be more active than the
CQ-bridged ferrocenyl derivatives while the later compounds,
viz. 110a–110e, retained their activity against the CQ-resistant
strains. SAR studies revealed the loss of activity with increased
branching while the length of alkyl spacer did not seem to
inuence their antiplasmodial proles. The physical properties,
viz. the presence or absence of hydrogen bonding interactions,
the degree of rigidity and the lipophilicity of these conjugates,
were correlated to their biological activity. A balance between
lipophilicity and hydrophilicity seemed to inuence the bio-
logical prole of the conjugates while the structural character-
istics, such as conformation and size, were found to be essential
to overcoming the drug resistance.
The methodology was further extended with the synthesis of
a new class of organometallic antimalarials comprising a
ferrocene nucleus tethered to a CQ analogue and a 1,2,3,5-
(diisopropylidene)-a-D-glucofuranose moiety in a 1,10-hetero-
annular substitution pattern. Synthesis of these compounds
was facilitated by orthogonal functionalization of ferrocene
resulting in 1-acetoxy-10-(1,3-dioxan-2-yl)ferrocene as a key
intermediate for the modular introduction of the carbohydrate.
This was followed by reductive amination with CQ derivatives,
yielding 1-[3-(7-chloroquinolin-4-ylamino)alkylamino]-10-[6-
(1,2;3,5-diisopropylidene)-a-D-glucofuranosidyl]ferrocenes 117–
119 (Fig. 16). These trifunctional hybrids were assessed for their
antiplasmodial activity against CQ-susceptible (D10) and
CQ-resistant (Dd2 and K1) strains of P. falciparum.97 No corre-
lation could be established between either the strength of
intramolecular H-bonding or the polar surface area and anti-
malarial potential of these compounds. Antiplasmodial studies
indicated that the activity of the synthesized compounds
(117–119) showed improvement in comparison to their either
1,2-disubstituted regio-isomers (114–116) or to
monosubstituted ferrochloroquines (111–113). The side chain
length linking CQ with the ferrocene molecule did not have any
effect on the observed activity.
Aer the discovery of FQ as a potential antimalarial drug, an
extensive study was carried out to explore its derivatives with
better activity, enhanced ADME properties and structure activity
relationship. In a recent study, 4-aminoquinoline, trioxane and
ferrocene were covalently linked to form a hybrid (120, Fig. 17)
with the aim of studying its antimalarial efficacy. The scaffold
revealed potent activity against CQ-resistant P. falciparum and
was further evaluated in vivo against P. vinckei petteri infected
mice. In vivo studies showed a marked decrease in the para-
sitemia to a lower than detectable level.98 Two new “half sand-
wich” (h6-arenequinoline) Cr(CO)3 complexes, viz. [h
6-N-(7-
chloroquinolin-4-yl)-N0-(2-dimethylaminomethylbenzyl)ethane-
1,2-diamine]tricarbonylchromium and [h6-N-(7-chloroquinolin-
4-yl)-N0-(2-dimethylaminobenzyl)-ethane-1,2-diamine]tricarbonyl-
chromium compounds (121 and 122, Fig. 17) were prepared and
tested in vitro for their antiplasmodial efficacy against
CQ-susceptible and CQ-resistant strains. The efficacy of complex
122 was twofold higher compared to the organic ligand.99 In
search of new efficient antimalarial complexes, Smith et al.
synthesized a series of poly(propylene-imine) dendrimers func-
tionalized with ferrocenyl thiosemicarbazones hybridized to the
periphery of the molecule (123, Fig. 17). These metallo-
dendrimers exhibited antiplasmodial activity in the low mM
range against theW2 strain of P. falciparum. Their antiplasmodial
potencies were better than non-conjugated ferrocenyl thioesters
as well as the free dendritic ligand.100 Further, organometallic
complexes, viz. cymantrene (CpMn(CO)3) and cyrhetrene
Scheme 17 Reagents and conditions: (a) MeOH, rt; (b) NaBH4,
MeOH, rt.
Fig. 15 CQ derivatives 108a–108e, mono-substituted CQ–ferrocenyl
compounds 109a–109e, and 1,10-disubstituted bridged CQ–ferro-
cenyl hybrids 110a–110e.
Fig. 16 Mono-, 1,2-disubstituted, 1,10-disubstituted ferrocenyl chlo-
roquine glucofuranose conjugates 111–113, 114–116 and 117–119.
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(CpRe(CO)3) tethered with 4-aminoquinolines, were reported
(124–126, Fig. 17) and bio-evaluated for their malarial potency
against D10 and Dd2 strains of P. falciparum. The low resistance
indices (RI) of these complexes indicated that these complexes of
manganese and ruthenium may act as a lead for further devel-
opment of new antimalarial compounds.101
Smith et al. in a recent communication synthesized a new
carbosilane congener of ferroquine (127, Fig. 17) by including
an organosilicon moiety in the side chain of ferroquine. The
carbosilane congener was further utilized for the synthesis of a
corresponding series of metal complexes of neutral hetero-
metallic ruthenium and rhodium (128–132), as shown in
Fig. 17. All the newly synthesized compounds were evaluated for
antiplasmodial activity against the NF54 and Dd2 strains of
P. falciparum. The presence of the trimethylsilyl group in
compound 127 exhibited superior activity (IC50 ¼ 7.32 nM) as
compared to ferroquine (IC50 ¼ 42.65 nM) against the NF54
strain. Among synthesized complexes, 130 was the most active
with IC50 values of 4.86 and 35.91 nM against NF54 and Dd2
strains, respectively.102
Kumar and co-workers reported the synthesis of a gallium(III)
complex with 7-chloroquinoline thiosemicarbazone as a
ligand with antimalarial efficacy against 3D7 strain of P.
falciparum (Scheme 18). The synthesized complex 134
exhibited improved antimalarial activity than lumefantrine
on 3D7 isolate of P. falciparum. Further, the synthesized
complex 134 was evaluated for anti-proliferative activity
against different cancer cell lines and complex proved to be
31 times more potent on colon cancer cell line HCT-116
compared with the standard drug etoposide with consider-
ably less cytotoxicity on non-cancerous colon broblast
CCD-18Co.103
Fig. 17 Some conjugates of ferroquine.
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2.10 Artemisinin and trioxaquine based 4-aminoquinoline
conjugates
The benets of molecular hybridization over combination
therapy can be well rationalized by the report of Walsh and co-
workers involving the synthesis of dihydroartemisinin–quinine
hybrids (139). The compound was prepared by following a
sequence of steps as shown in Scheme 19 involving an initial
protection of quinine with TBDMSiCl with subsequent oxida-
tion to form carboxylic acid and coupling with dihy-
droartemisinin.45 The antimalarial efficacy of the synthesized
hybrids was determined against CQ-sensitive 3D7 and
CQ-resistant FcB1 strains of P. falciparum. The conjugate proved
to be more potent than either quinine or dihydroartemisinin
while a three-fold improvement in efficacy was observed over a
1 : 1 mixture of quinine and dihydroartemisinin.
Rationalization of literature has revealed that the variation
in the length of alkyl chain between two nitrogen atoms of the
4-diaminoalkyl side chain has a marked inuence on the anti-
malarial efficacy. The compounds with either smaller alkyl
chain length (n ¼ 2–4) or with longer alkyl chain length (n ¼
10–12) retained their activities against CQ-resistant strains,
whereas the compounds with chain length n ¼ 5–8 showed a
relative decrease in the activity.104 Chibale and co-workers
exploited a molecular hybridization protocol for the prepara-
tion of dihydroartemisinin–7-chloroquinoline conjugates (141
and 143) prepared via aza-Michael addition reaction along with
the analogues of dihydroartemisinin (DHA) derivatives 142
(Scheme 20). These were tested for their antimalarial proles
against CQ-sensitive (D10) and CQ-resistant (Dd2) strains of
P. falciparum. The length of alkyl chain introduced as the spacer
was chosen to be between 2 and 6 carbon atoms for optimal
biological activity.105 The evaluation data revealed a substantial
increase in antimalarial efficacy of the hybrids over the
precursors 7 or 28 while a decrease in antimalarial efficacy was
observed with the increase in chain length. DHA derivatives
prepared via aza-Michael addition with available amines were
found to be more effective in the growth inhibition of P. falci-
parum suggestive of the fact that the DHA nucleus is mainly
responsible for the observed antimalarial activity of the hybrids.
The target compound 141 and three dihydroartemisinin deriv-
atives of 125 showed excellent antiplasmodial activity with IC50
values of #10 nM against both D10 and Dd2 strains of P. fal-
ciparum and low cytotoxicity against human cell lines (HeLa
cells).
N'Da further extended his work on the synthesis of artemi-
sinin–quinolines and their hybrid-dimers from dihy-
droartemisinin and aminoquinolines (Scheme 21).106 The
synthesized hybrids (145) obtained as b-isomers were assessed
for their antiplasmodial activity against CQ-sensitive and
-resistant strains of P. falciparum along with cytotoxicity proles
against a mammalian cell-line. Although none of the hybrids
was found to be more potent than DHA, two were more active
than CQ. A hybrid-dimer with an optimum chain length of three
carbon atoms displayed excellent antimalarial potency, with
IC50 values of 5.31 and 28.43 nM against D10 and Dd2 strains of
P. falciparum.
Scheme 18 Reagents and conditions: (a) Ga(NO)3$H2O, ethanol,
reflux, 2 h.
Scheme 19 Reagents and conditions: (a) TBDMSCl, Et3N, DMAP, DMF,
rt; (b) (i) BH3-THF, diglyme, 0 C; (ii) Me3NO$2H2O, 100 C; (iii) Jones
reagent, acetone, rt; (c) (i) 2,6-dichlorobenzoyl chloride, Et3N, DMAP,
DCM, rt; (ii) TBAF, THF, rt.
Scheme 20 Reagents and conditions: (a) appropriate amine, DBU,
CH3CN, rt, 12 h; (b) DBU, DMF, N2, rt, 12 h.
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N'Da with his co-workers explored the synthesis of dihy-
droartemisinin–4-aminoquinoline conjugates (146, 147 and 148)
with their subsequent conversion to oxalate salts (Scheme 22). In
vitro antimalarial activity was tested against CQ-sensitive D10 and
-resistant Dd2 strains of P. falciparum while cytotoxicity was
determined againstmammalian Chinese Hamster Ovarian (CHO)
via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT)-assay.107 Most of the synthesized conjugates showed
comparable to higher activity to that of the standard drug CQwith
IC50s ranging from 17.2 to 38.9 nM. The oxalate salts proved to be
seven times more potent than the standard drug CQ against the
CQ-resistant strain of P. falciparium.
In 2011, Chibale et al. extended the synthesis of artemisinin–
4-aminoquinoline conjugates (151, 152) viaUgi four-component
condensation (Ugi-4CR) reaction (Scheme 23)108 using para-
formaldehyde as aldehyde component, 7-chloro-4-
diaminoalkylquinoline as the amine input, artelinic acid/1,4-
napthoquinone acid as acid input, and cyclohexyl-or tert-butyl
isocyanide as the isocyanide input. Antiplasmodial studies of
the synthesized conjugates showed comparable potency against
CQ-resistant K1 and CQ-sensitive D10 strains of P. falciparum.
Mechanistically, the conjugates exhibited potent inhibitory
activities of b-hematin formation and appeared to inhibit
endocytosis as evident by the decrease in the number of trans-
port vesicles in the parasite.
Meunier et al. reported the synthesis of trioxaquines 154 as
potential antimalarials by following the synthetic protocol as
depicted in Scheme 24.109 Compound trioxaquine (PA1103/
SAR116242) 154, obtained from this study, proved to be highly
active against several sensitive and resistant strains of P. falci-
parum at nM concentrations. It has also shown activity on
multidrug-resistant strains attained from fresh patient isolates
in Gabon along with good drug proles viz. absorption,
metabolism and safety parameters. Efficacy of this conjugate via
oral route is very high with total curing of mice infected withCQ-
sensitive and -resistant strains of Plasmodium at 26–32 mg kg1.
The selection of trioxaquine (PA1103/SAR116242) for anti-
malarial drug development strongly conrms the role of
molecular hybridization in furnishing molecules with satisfac-
tory pharmacological and safety proles to allow regulatory
drug development. Guided by similar rationale, O'Neill and co-
workers reported the synthesis of semi-synthetic trioxaquines
and trioxolaquines in excellent yields and assessed their anti-
malarial activities against CQ-sensitive (3D7) and -resistant (K1)
strain of P. falciparum. Compounds of both the series showed
activity in low nM range with some of the analogues being more
active than artemisinin. The structure of two of the most active
compounds 155 and 156 of the series is as shown in Fig. 18.110
2.11 Miscellaneous antimalarial 4-aminoquinoline
conjugates
A library of tetrahydro-1H-b-carbolines–4-aminoquinoline
hybrids 159 were identied as a novel class of highly potent
antimalarial agents by Chauhan et al. using molecular hybrid-
ization approach with MIC values ranging from 0.05 to
19.08 mM against CQ-sensitive strain NF-54 of P. falciparum
(Scheme 25).111 Most potent of the synthesized conjugate was
Scheme 21 Reagents and conditions: (a) DMF, 90–110 C, 6–8 h.
Scheme 22 Reagents and conditions: (a) DMF, 70–80 C, 4–6 h.
Scheme 23 Reagents and conditions: (a) succinic acid, silver nitrate,
ammonium persulfate, 30% aq. CH3NH2, 65–70 C, 3 h.
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found to have seven folds more activity than the standard drug
CQ and therefore warrants the development of these hybrids in
antimalarial chemotherapy.
In 2011, Egan and collaborators proposed the synthesis of
dibemethin-coupled 4-aminoquinolines 162 as potential anti-
malarial agents with a view to obtain novel hybrids capable of
inhibition of hemozoin formation in the digestive vacuole of
parasite (Scheme 26).112 These hybrids were equally potent
against cultured CQ-sensitive (D10) and CQ-resistant (K1)
P. falciparum. Several compounds exhibited in vitro antimalarial
potency below 100 nM against both strains of the parasite while
none of compound exhibited cross-resistance with the standard
drug CQ. The compounds with promising in vitro activity and
non-cytotoxicity against mammalian cell line were screened for
their in vivo activity against P. berghei. The active compounds
exhibited signicant in vivo activity and reduces parasitemia by
over 99%. SAR studies showed marked dependence of activity
on the site of attachment of 4-aminoquinoline with side chain
of dibemethin as well as the substituent on the terminal phenyl
ring of dibemethin. Researchers further investigated the inter-
action of this series of compounds with CQ transport by making
use of the Xenopus oocyte expression system, which directly
measures CQ transport by P. falciparum CQ-resistance trans-
porter (PfCRT) and its inhibition with potential resistance-
reversers or reversed-CQ compounds. The results of this study
conrmed 4-aminoquinoline–dibemethin hybrids as the rst
example of reversed-CQ antimalarials with capability to inhibit
both PfCRT and hemozoin formation.
Recently, Chibale et al. reported the design and synthesis of
novel b-amino alcohol derivatives of 4-aminoquinoline (164)
with an extension to 4-aminoquinoline–oxazolidinone conju-
gates (165, Scheme 27).113 In vitro antimalarial activity was
evaluated against CQ-sensitive (3D7) and CQ-resistant (K1)
strains of P. falciparum. Few of the b-amino alcohol analogues
were more active compared to CQ against the CQ-sensitive
strain while the potency decreased considerably against the
CQ-resistant strain, revealing cross resistance of these conju-
gates with CQ. The conversion of b-amino alcohol to oxazoli-
dinones by reacting with tris-phosgene resulted in a
considerable decrease in the activities of the synthesized
conjugates against both CQ-sensitive and CQ-resistant strains.
Chauhan et al. synthesized sixteen new 4-aminoquinoline
analogues by modifying its side chain with an extension
towards the synthesis of quinoline–acridine conjugates and
tested their in vitro antiplasmodial activity against the NF 54
strain of P. falciparum.114 Among the tested compounds, the
compound 166 (MIC¼ 0.125 mg ml1) was nearly as active as CQ
(MIC¼ 0.125 mgml1) while another (167; MIC¼ 0.031 mgml1)
exhibited four-fold more potency than CQ. Three of the selected
test compounds (166, 167 and 168; Fig. 19) with good in vitro
antiplasmodial potency were chosen for in vivo screening in
Swiss mice infected with the CQ-resistant N-67 strain of P. yoelii.
Compound 167 showed a curative response to all treated Swiss
mice at doses of 50 mg kg1 and 25 mg kg1 for 4 days given via
intra-peritoneal route. The compound was orally active at the
dose of 100 mg kg1 and has proved the importance of
exploring the 4-aminoquinoline class for the discovery of new
antimalarial agents.
The hybrid design strategy was further exemplied by
Whitlock and co-workers in the synthesis of CQ–astemizole
(non-sedating H1 antagonist) conjugates 170 along with their
antiplasmodial evaluation against K1 strain of P. falciparum
(Fig. 20).115 Most of the conjugates were three to four folds more
potent than CQ with the most potent of the tested compound
exhibiting an IC50 of 23 nM. Importantly, the compounds dis-
played more than 100 times selectivity for antiparasitic activity
over cell-based cytotoxicity. Based on the preliminary in vitro
P. falciparum activity, two potent compounds were further
screened for in vivo studies on a P. berghei mouse malaria
model.
Scheme 24 Reagents and conditions: (a) NaBH3CN, MeOH, HCl/i-
PrOH.
Fig. 18 Most potent 1,2,4-trioxaquines and 1,2,4-trioxolaquines
conjugates.
Scheme 25 Reagents and conditions: (a) DMF, 120 C, high pressure.
Scheme 26 Reagents and conditions: (a) anhyd. N-methyl-2-pyrro-
lidine, K2CO3, Et3N.
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Santos and colleagues synthesized molecular hybrids of
commercially available squarates with the antimalarial drugs,
chloroquine (CQ) and primaquine (PM) with improved anti-
plasmodial activity compared with the squarates.116 Three of the
synthesized conjugates containing two 7-chloroquinoline
moieties were two fold more active than the standard drug, CQ
with IC50 values ranging from 0.095–0.20 mM against the
CQ-resistant W2 strain of P. falciparum (Fig. 21). The length of
the carbon chain introduced as the linker between the squa-
rates and quinoline scaffolds has been shown to have a major
impact on the observed activity proles with the activity
generally increasing with the increase in chain length.
Vacuolar plasmepsins, pepsin-like aspartic proteases present
in different species of the parasite Plasmodium, are recognized
as promising targets for the enlargement of new antimalarial
agents.117 They comprise plasmepsins 1 (PLM 1), plasmepsins 2
(PLM 2), plasmepsins 4 (PLM 4) and a histo-aspartic protease
(HAP) and play a vital role in the survival of the parasite. These
enzymes are contained in the food vacuole of the parasite and
are directly involved in the degradation of human haemoglobin
during the erythrocytic stage. Statin-based molecules are shown
to be potent inhibitors of PLMs, however with restricted effec-
tiveness in killing the parasite (IC50 range 2–20 mM).117 In 2012,
Romeo and co-workers, in an attempt to circumvent the limi-
tations associated with statin-based molecules, synthesized its
hybrids with 4-aminoquinoline 172.118 It was considered that
since both of these molecules interfere with the haemoglobin
catabolism process, the resulting hybrid would have an
improvement in overall antimalarial potency.119 Two of the
4-aminoquinoline–statin hybrids (172a and 172b) were more
potent than CQ against the CQ-resistant strain (Fig. 22) with
good selectivity against cathepsin D. It was concluded from
b-hematin inhibitory assay that the 7-chloro group in the
quinoline ring is obligatory for the antiplasmodial efficacy of
the synthesized conjugates.
Chibale and co-workers reported the preparation of 4-ami-
noquinoline–3-hydroxypyridin-4-one conjugates on the basis of
additive in vitro combination of N-alkyl-3-hydroxypyridin-4-one
with chloroquine (CQ) (Scheme 28). All the synthesized conju-
gates were assessed in vitro against CQ-resistant (K1 and W2)
and -sensitive (3D7) strains of P. falciparum along with
b-hematin formation studies.120 Most of the conjugates were
shown to have superior b-hematin inhibition activity to that of
CQ and a strong correlation was observed between antimalarial
proles and inhibition of b-hematin formation. Among the
synthesized conjugates, three potent compounds with longer
alkyl chains (n ¼ 3, 5) against K1, 3D7, and W2, respectively,
having IC50s of 175c (0.13, 0.004, and 0.1 mM); 175d (0.08, 0.01,
and 0.02 mM); and 174g (0.07, 0.03, and 0.08 mM). A cytotoxicity
study on a mammalian cell line showed that most of the
conjugates screened were non-cytotoxic and far less toxic than
podophyllotoxin (POD).
Another attempt to explore the antimalarial potential of bis-
quinolines was made by N'Da and co-workers by exploring the
synthesis of a series of bis-quinolines and bis-pyrrolo[1,2a]
quinoxalines containing various polyamine linkers along with
the determination of their aqueous solubility and distribution
coefficients (Scheme 29).121 The antimalarial potency of these
compounds was assessed against CQ-sensitive (D10) and CQ-
resistant (Dd2) strains of P. falciparum besides the growth
inhibitory studies against a panel of cancer cell lines. Bis-
quinolines showed a general increase in antimalarial activity
Scheme 27 Reagents and conditions: (a) MeOH, 55 C; (b) tris-
phosgene, DCM, 0 C-rt.
Fig. 19 Most potent compounds among the series.
Fig. 20 General strategy of 7-chloroquinoline–astemizole based
hybrids. Fig. 21 Most potent 4-aminoquinoline–squarate hybrids and CQ.
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with the increase in protonation sites given by polyamine
linkers that could help to overcome CQ-resistance. The
7-chloro-substituted hybrids have been shown to possess more
potency compared to either 5-methyl quinoline or pyrrolo[1,2a]
quinoxaline conjugates. Among the bis-quinoline, triethylene-
tetramine and N,N-bis(3-aminopropyl)ethylene-diamine
linkers were found to be the most potent of all the synthe-
sized conjugates.
Chibale et al. explored the molecular hybridization paradigm
for the synthesis of three groups of hybridmolecules by covalent
fusion of azidothymidine (AZT) with dihydroartemisinin (DHA),
a tetraoxane or a 4-aminoquinoline derivative that target
P. falciparum and HIV simultaneously. All synthesized
compounds were tested for their inhibitory activity against
pseudotyped HIV-1, CQ-sensitive (3D7) and CQ-resistant (Dd2)
strains of P. falciparum at three different concentrations (50, 5
and 1 mM) along with cytotoxicity assessment against HeLa
cells. Among the tested conjugates, a potent CQ–AZT conjugate
(180, Fig. 23) exhibited IC50 values of 0.38 and 0.08 mM (more
potent than CQ and tetraoxane) against 3D7 and Dd2 strains of
P. falciparum, respectively. This compound also exhibited
enhanced inhibitory activity (IC50 value of 0.9 mM) against
pseudotyped HIV-1 with a selective index of 31.8. However,
higher cytotoxicity in HeLa cells discontinued its further
testing.122
In a recent communication, Rao et al. reported the synthesis
of a series of 4-aminoquinoline–4H-chromene conjugates along
with their antimalarial evaluation against two P. falciparum
strains, namely 3D7 (CQ-sensitive) and K1 (CQ-resistant).123 All
synthesized conjugates possessed activity in the mM range with
compounds 181 having piperazine linkage and nitro substit-
uent and 182with azapane linkage and chloro substituent at the
C-6 position of 4H-chromene showing comparable activity to
that of CQ (Fig. 24). Further, molecular docking suggested that
these conjugates exhibited strong binding affinity with P. falci-
parum lactate dehydrogenase (PfLDH) and act as potent inhib-
itors of the parasite specic glycolytic pathway.
Chibale et al. recently disclosed the synthesis of 4-amino-
quinoline–benzoxazole conjugates and screened for their anti-
malarial efficacy against K1 (multidrug resistant) and NF54
(sensitive) strains of the parasite P. falciparum.124 The anti-
plasmodial activities of the synthesized compounds exhibited a
good structure–activity relationship, which led to the recogni-
tion of highly promising conjugates having IC50s in the nM
range against both K1 and NF54 strains of P. falciparum.
Further, the synthesized conjugates showed good in vitro
microsomal metabolic stability along with desirable in vivo
Fig. 22 Most potent 4-aminoquinoline–statin hybrids 171a, 171b,
171c.
Scheme 28 Reagents and conditions: (a) 50% aq. EtOH, pH 13 (2 M
NaOH), 90–120 C, 18–24 h; (b) H2, Pd/C, 2 M ethanolic HCl, 4 atm or
1 : 2 : 3 H2O/EtOH/HCl, 74 C, 24 h.
Scheme 29 Reagents and conditions: (a) 135–145 C, 16–20 h; (b)
K2CO3, DMF, 135–145 C, 16 h.
Fig. 23 Most potent CQ–AZT compound 180.
Fig. 24 Most potent 7-chloroquinoline–4H-chromene conjugates
181 and 182.
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pharmacokinetic results. The four most promising conjugates
(183, 184, 185 and 186, Fig. 25) were subjected to in vivo anti-
malarial studies against P. berghei infected mice. Compound
183 showed good in vivo oral efficacy and completely cured the
treated mice at a low multiple dose of 4–10 mg kg1. Mecha-
nistic studies revealed the inhibition of hemozoin formation as
one of the probable mechanisms of action for these
compounds. Further, b-haematin inhibition studies conrmed
the importance of the quinoline nucleus for antiplasmodial
activity as non-benzoxazole intermediates did not show any
inhibitory activity even at highest tested concentration.
Lopez and co-workers in a recent communication showed
the synthesis of 30-dehydroxy-isotebuquine analogs of 4-ami-
noquinoline 192 via a ve step synthetic sequence in good to
excellent yields as shown in Scheme 30. The synthesized
conjugates were assessed for their b-hematin inhibitory activity.
Among eight of the synthesized conjugates, six compounds
were shown to have greater than 97% IHF value (% inhibition of
hemozoin formation). These potent compounds were further
tested for their in vivo antimalarials activity in mice infected
with P. berghei ANKA CQ-susceptible strain with three of the
conjugates displaying in vivo antimalarial efficacy comparable
to that of CQ.125
3. Conclusions
The development of new drugs with improved physicochemical
proles, lack of toxicity, synthetic selectivity and economic
accessibility represents a big challenge for the pharmaceutical
sector and warrants continuous efforts. The present review
establishes the attention of organic medicinal chemists in the
eld of 4-aminoquinoline-hybridization towards the synthesis
of new molecular frameworks for averting and delaying the
emergence of drug resistance along with the improvement of
efficacy. The validation of molecular hybridization, however, is
crucial and the benet of the hybrid over the separate phar-
macophores or their 1 : 1 combination should be conrmed.
Notes and references
1 T. Bishop and P. Sham, Analysis of Multifactorial Diseases,
Academic Press, New York, 2000, pp. 1–320.
2 M. H. Cohen, G. A. Williams, R. Sridhara, G. Chen,
W. D. J. McGuinn, D. Morse, S. Abraham, A. Rahman,
C. Liang, R. Lostritto, A. Baird and R. Pazdur, Clin. Cancer
Res., 2004, 35, 1212.
3 S. Frantz, Nature, 2005, 437, 942.
4 H. Takano, K. Sawada, N. Sato, A. Natoya, T. Tarumi,
S. Hirayama, K. Koizumi, T. A. Takahashi, S. Sekiguchi
and T. Koike, Leuk. Lymphoma, 1996, 21, 473.
5 B. A. Larder, S. D. Kemp and P. R. Harrigan, Science, 1995,
269, 696.
6 S. A. Eisen, D. K. Miller, R. S. Woodward, E. Spitznagel and
T. R. Przybeck, Arch. Intern. Med., 1990, 150, 1881.
7 N. S. Skolnik, J. D. Beck and M. Clark, Am. Fam. Physician,
2000, 61, 3049.
8 G. Glass, Nat. Rev. Drug Discovery, 2004, 3, 731.
9 W. H. Frishman and A. L. Zuckerman, Expert Rev.
Cardiovasc. Ther., 2004, 2, 675.
10 N. A. Flores, Curr. Opin. Invest. Drugs, 2004, 5, 984.
11 T. N. C. Wells, P. L. Alonso and W. E. Gutteridge, Nat. Rev.
Drug Discovery, 2009, 8, 879.
12 P. G. Clay, T. A. H. Taylor, A. G. Glaros, M. P. McRae,
C. Williams, D. McCandless and M. Oelklaus, Ther. Clin.
Risk Manage., 2008, 4, 291.
13 R. Morphy and Z. Rankovic, J. Med. Chem., 2005, 48, 6523.
14 B. Meunier, Acc. Chem. Res., 2008, 4, 69.
15 F. W. Muregi and A. Ishih, Drug Dev. Res., 2010, 71, 20.
16 C. Viegas-Junior, A. Danuello, V. D. S. Bolzani, E. J. Barreiro
and C. A. M. Fraga, Curr. Med. Chem., 2007, 14, 1829.
17 C. A. M. Fraga, Expert Opin. Drug Discovery, 2009, 4, 605.
18 R. Morphy and Z. Rankovic, Curr. Pharm. Des., 2009, 15,
587.
19 J. O. Gyapong, M. Gyapong, N. Yellu, K. Anakwah,
G. Amofah, M. Bockarie and S. Adjiei, Lancet, 2010, 375,
160.
20 World Health Organization, Global report for research on
infectious diseases of poverty, 2012, http://whqlibdoc.who.int/
publications/2012/9789241564489_eng.pdf.
Fig. 25 Most potent 7-chloroquinoline–benzoxazole conjugates 183,
184, 185 and 186.
Scheme 30 Reagents and conditions: (a) phenylboronic acid, toluene,
Pd(PPh3)4 (5%), K2CO3, EtOH : H2O (1 : 1), 100 C, 24 h; (b) NBS, CCl4,
(PhCO)2O2, light, reflux, 24 h; (c) dialkylamine, toluene, reflux, 6 h; (d)
Sn/HCl, 70 C, 2 h; (e) 4,7-dichloroquinoline, EtOH, HCl (cat.), reflux, 6 h.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 82676–82698 | 82695
Review RSC Advances
Pu
bl
ish
ed
 o
n 
11
 S
ep
te
m
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/3
0/
20
20
 3
:1
6:
12
 A
M
. 
View Article Online
21 WHO, World Malaria Report, 2013, http://www.who.int/
malaria/publications/world malaria report 2013/en/
index.html.
22 R. Banerjee, J. Liu, W. Beatty, L. Pelosof, M. Klemba and
D. E. Goldberg, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 990.
23 N. D. Gamboa de Domı´nguez and P. J. Rosenthal, Blood,
1996, 87, 4448.
24 P. Loria, S. Miller, M. Foley and L. Tilley, Biochem. J., 1999,
339, 363.
25 C. D. Fitch, R. Chevli, P. Kanjananggulpan, P. Dutta,
K. Chevli and A. C. Chou, Blood, 1983, 62, 1165.
26 T. Yoshida and T. C. Migita, J. Inorg. Biochem., 2000, 82, 33.
27 K. A. de Villiers and T. J. Egan, Molecules, 2009, 14, 2868.
28 T. J. Egan and H. M. Marques, Coord. Chem. Rev., 1999, 190,
493.
29 T. J. Egan, R. Hunter, C. H. Kaschula, H. M. Marques,
A. Misplon and J. Walden, J. Med. Chem., 2000, 43, 283.
30 M. Schlitzer, Curr. Med. Chem., 2007, 2, 944.
31 V. Narasimhan and A. Attaran, Malar. J., 2003, 2, 8.
32 T. E. Wellems, Science, 2002, 298, 124.
33 A. B. S. Sidhu, D. Verdier-Pinard and D. A. Fidock, Science,
2002, 298, 210.
34 G. Edwards and G. A. Biagini, Br. J. Clin. Pharmacol., 2006,
61, 690.
35 T. K. Mutabingwa, Acta Trop., 2005, 5, 305.
36 R. T. Eastman and D. A. Fidock,Nat. Rev. Microbiol., 2009, 7,
864.
37 A. M. Dondorp, F. Nosten, P. Yi, D. Das, A. P. Phyo,
J. Tarning, K. M. Lwin, F. Ariey, W. Hanpithakpong,
S. J. Lee, P. Ringwald, K. Silamut, M. Imwong,
K. Chotivanich, P. Lim, T. Herdman, S. S. An, S. Yeung,
P. Singhasivanon, N. P. Day, N. Lindegardh, D. Socheat
and N. J. White, N. Engl. J. Med., 2009, 361, 455.
38 O. Dechy-Cabaret, F. Benoit-Vical, C. Loup, A. Robert,
H. Gornitzka, A. Bonhoure, H. Vial, J. F. Magnaval,
J. P. Seguela and B. Meunier, Chem.–Eur. J., 2004, 10, 1625.
39 F. Bellot, F. Cosledan, L. Vendier, J. Brocard, B. Meunier
and A. Robert, J. Med. Chem., 2010, 53, 4103.
40 A. Kumar, K. Srivastava, S. R. Kumar, M. I. Siddiqi,
S. K. Puri, J. K. Saxena and P. M. S. Chauhan, Eur. J. Med.
Chem., 2011, 46, 676.
41 S. Manohar, M. Tripathi and D. S. Rawat, Curr. Top. Med.
Chem., 2014, 14, 1706.
42 E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal,
R. Bhampidipati, A. Kopinathan, P. J. Smith and K. Chibale,
J. Med. Chem., 2011, 54, 3637.
43 F. Bellot, F. Cosledan, L. Vendier, J. Brocard, B. Meunier
and A. Robert, J. Med. Chem., 2010, 53, 4103.
44 A. Robert, O. Dechy-Cabaret, J. Cazelles and B. Meunier,
Acc. Chem. Res., 2002, 35, 167; F. Benoit-Vical, J. Lelievre,
A. Berry, C. Deymier, O. Dechy-Cabaret, J. Cazelles,
C. Loup, A. Robert, J. F. Magnaval and B. Meunier,
Antimicrob. Agents Chemother., 2007, 51, 1463.
45 J. J. Walsh, D. Coughlan, N. Heneghan, C. Gaynor and
A. Bell, Bioorg. Med. Chem. Lett., 2007, 17, 3599.
46 I. Opsenica, D. Opsenica, C. A. Lanteri, L. Anova,
W. K. Milhous, K. S. Smith and B. A. Salaja, J. Med.
Chem., 2008, 51, 6216.
47 S. Gemma, G. Campiani, S. Butini, B. P. Joshi, G. Kukreja,
S. S. Coccone, M. Burrutti, M. Persico, V. Nacci, I. Fiorini,
E. Novellino, D. Taramerlli, N. Banilico, S. Parapini,
V. Yardley, S. Cro, S. K. Maerk, M. Rottman, R. Brun,
M. Coletta, S. Marini, G. Guiso, S. Caccia and
C. Fattorusso, J. Med. Chem., 2009, 52, 502.
48 I. Chiyanzu, C. Clarkson, P. J. Smith, J. Gut, P. J. Rosenthal
and K. Chibale, Bioorg. Med. Chem., 2005, 13, 3249.
49 C. E. Gutteridge, D. A. Nichols, S. M. Curtis, D. S. Thota,
J. V. Vo, L. Gerena, G. Montip, C. O. Asher, D. S. Diaz,
C. A. DiTusa, K. Smith and A. K. Bhattacharjee, Bioorg.
Med. Chem. Lett., 2006, 16, 5682.
50 M. Liu, P. Wilairat and M. L. Go, J. Med. Chem., 2001, 44,
4443.
51 M. Chen, T. G. Theander, S. B. Christensen, L. Hviid, L. Zhai
and A. Kharazmi, Antimicrob. Agents Chemother., 1994, 38,
1470.
52 M. Chen, S. B. Christensen, L. Zhai, M. H. Rasmussen,
T. G. Theander, S. Frøkjaer, B. Steffansen, J. Davidsen and
A. Kharazmi, J. Infect. Dis., 1997, 176, 1327.
53 N. Sriwilaijaroen, M. Liu, M. L. Go and P. Wilairat, Southeast
Asian J. Trop. Med. Public Health, 2006, 37, 607.
54 J. N. Dominguez, J. E. Charris, G. Lobo, N. G. de
Dominguez, M. M. Moreno, F. Riggione, E. Sanchez,
J. Olson and P. J. Rosenthal, Eur. J. Med. Chem., 2001, 36,
555.
55 M. L. Go, M. Liu, P. Wilairat, P. J. Rosenthal, K. J. Saliba and
K. Kirk, Antimicrob. Agents Chemother., 2004, 48, 3241.
56 E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal,
P. J. Smith and K. Chibale, Bioorg. Med. Chem., 2010, 18,
8243.
57 K. V. Sashidhara, M. Kumar, R. K. Modukuri,
R. K. Srivastava, A. Soni, K. Srivastava, S. V. Singh,
J. K. Saxena, H. M. Gauniyal and S. K. Puri, Bioorg. Med.
Chem., 2012, 20, 2971.
58 K. V. Sashidhara, S. R. Avula, G. R. Palnati, S. V. Singh,
K. Srivastava, S. K. Puri and J. K. Saxena, Bioorg. Med.
Chem. Lett., 2012, 22, 5455.
59 B. Insuasty, A. Montoya, D. Becerra, J. Quiroga, R. Abonia,
S. Robledo, I. D. Ve´lez, Y. Upegui, M. Nogueras and
J. Cobo, Eur. J. Med. Chem., 2013, 67, 252.
60 F. J. Smit and D. D. N'Da, Bioorg. Med. Chem., 2014, 22,
1128.
61 S. Manohar, U. C. Rajesh, S. I. Khan, B. L. Tekwani and
D. S. Rawat, ACS Med. Chem. Lett., 2012, 3, 555.
62 K. Singh, H. Kaur, K. Chibale, J. Balzarini, S. Little and
P. V. Bharatam, Eur. J. Med. Chem., 2012, 52, 82.
63 S. I. Pretorius, W. J. Breytenbach, C. de Kock, P. J. Smith and
D. D. N'Da, Bioorg. Med. Chem., 2012, 21, 269.
64 A. Thakur, S. I. Khan and D. S. Rawat, RSC Adv., 2014, 4,
20729.
65 D. Kumar, S. I. Khan, B. L. Tekwani, P. Ponnan and
D. S. Rawat, Eur. J. Med. Chem., 2015, 89, 490.
82696 | RSC Adv., 2015, 5, 82676–82698 This journal is © The Royal Society of Chemistry 2015
RSC Advances Review
Pu
bl
ish
ed
 o
n 
11
 S
ep
te
m
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/3
0/
20
20
 3
:1
6:
12
 A
M
. 
View Article Online
66 S. Manohar, S. I. Khan and D. S. Rawat, Chem. Biol. Drug
Des., 2011, 78, 124.
67 A. Kumar, K. Srivastava, S. R. Kumar, M. I. Siddiqi,
S. K. Puri, J. K. Sexana and P. M. S. Chauhan, Eur. J. Med.
Chem., 2011, 46, 676.
68 H. R. Bhat, U. P. Singh, P. Gahtori, S. K. Ghosh, K. Gogoi,
A. Prakash and R. K. Singh, New J. Chem., 2013, 37, 2654.
69 H. R. Bhat, U. P. Singh, P. Gahtori, S. K. Ghosh, K. Gogoi,
A. Prakash and R. K. Singh, RSC Adv., 2013, 3, 2942.
70 F. A. Rojas Ruiz, R. N. Garc´ıa-Sa´nchez, S. V. Estupin˜an,
A. Go´mez-Barrio, D. F. Torres Amado, B. M. Pe´rez-
Solo´rzano, J. J. Nogal-Ruiz, A. R. Mart´ınez-Ferna´ndez and
V. V. Kouznetsov, Bioorg. Med. Chem., 2011, 19, 4562.
71 K. Chauhan, M. Sharma, J. Saxena, S. V. Singh, P. Trivedi,
K. Srivastava, S. K. Puri, J. K. Saxena, V. Chaturvedi and
P. M. S. Chauhan, Eur. J. Med. Chem., 2013, 62, 693.
72 V. R. Solomon, W. Haq, K. Srivastava, S. K. Puri and
S. B. Katti, J. Med. Chem., 2007, 50, 394.
73 S. Gemma, G. Campiani, S. Butini, G. Kukreja,
S. S. Coccone, B. P. Joshi, M. Persico, V. Nacci, I. Fiorini,
E. Novellino, E. Fattorusso, O. Taglialatela-Scafati,
L. Savini, D. Taramelli, N. Basilico, S. Parapini,
G. Morace, V. Yardley, S. Cro, M. Coletta, S. Marini and
C. Fattorusso, J. Med. Chem., 2008, 51, 1278.
74 S. Gemma, C. Camodeca, S. S. Coccone, B. P. Joshi,
M. Bernetti, V. Moretti, S. Brogi, M. C. B. de Macros,
L. Savini, D. Taramelli, N. Basilico, S. Parapini,
M. Rottmann, R. Brun, S. Lamponi, S. Caccia, G. Guiso,
R. L. Summers, R. E. Martin, S. Saponara, B. Gorelli,
E. Novellino, G. Campiani and S. Butini, J. Med. Chem.,
2012, 55, 6948.
75 C. Ohrt, G. D. Willingmyre, P. Lee, C. Knirsch and
W. Milhous, Antimicrob. Agents Chemother., 2002, 46, 2518.
76 A. E. Yeo and K. H. Rieckmann, Int. J. Parasitol., 1995, 25,
531.
77 A. B. Sidhu, Q. Sun, L. J. Nkrumah, M. W. Dunne,
J. C. Sacchettini and D. A. Fidock, J. Biol. Chem., 2007,
282, 2494.
78 M. Peric´, A. Fajdetic´, R. Rupcˇic´, S. Alihodzˇic´, D. Ziher,
M. Bukvic´ Krajacˇic´, K. S. Smith, Z. Ivezic´-Scho¨nfeld,
J. Padovan, G. Landek, D. Jelic´, A. Hutinec, M. Mesic´,
A. Ager, W. Y. Ellis, W. K. Milhous, C. Ohrt and
R. Spaventi, J. Med. Chem., 2012, 55, 1389.
79 D. Pesic, K. Starcevic, A. Toplak, E. Herreros, J. Vidal,
M. J. Almela, D. Jelic, S. Alihodzic, R. Spaventi and
M. Peric, J. Med. Chem., 2012, 55, 3216.
80 P. Singh, P. Singh, M. Kumar, J. Gut, P. J. Rosenthal,
K. Kumar, V. Kumar, M. P. Mahajan and K. Bisetty,
Bioorg. Med. Chem. Lett., 2012, 22, 57.
81 R. Raj, C. Biot, S. Carre`re-Kremer, L. Kremer, Y. Gue´rardel,
J. Gut, P. J. Rosenthal and V. Kumar, Chem. Biol. Drug Des.,
2014, 83, 191.
82 P. Singh, R. Raj, P. Singh, J. Gut, P. J. Rosenthal and
V. Kumar, Eur. J. Med. Chem., 2014, 71, 128.
83 R. Raj, V. Mehra, J. Gut, P. J. Rosenthal, K. J. Wicht,
T. J. Egan, M. Hopper, L. A. Wrischnik, K. M. Land and
V. Kumar, Eur. J. Med. Chem., 2014, 84, 425.
84 S. P. Kumar, J. Gut, R. C. Guedes, P. J. Rosenthal,
M. M. M. Santos and R. Moreira, Eur. J. Med. Chem., 2011,
46, 927.
85 R. Raj, P. Singh, P. Singh, J. Gut, P. J. Rosenthal and
V. Kumar, Eur. J. Med. Chem., 2013, 62, 590.
86 R. Raj, J. Gut, P. J. Rosenthal and V. Kumar, Bioorg. Med.
Chem. Lett., 2014, 24, 756.
87 R. Raj, C. Biot, S. Carre`re-Kremer, L. Kremer, Y. Gue´rardel,
J. Gut, P. J. Rosenthal, D. Forge and V. Kumar, Chem. Biol.
Drug Des., 2014, 83, 622.
88 Nisha, J. Gut, P. J. Rosenthal and V. Kumar, Eur. J. Med.
Chem., 2014, 84, 566.
89 G. Gasser and N. Metzler-Nolte, Curr. Opin. Chem. Biol.,
2012, 16, 84.
90 C. Biot, W. Castro, C. Y. Botte and M. Navarro, Dalton
Trans., 2012, 41, 6335; C. G. Hartinger and P. J. Dyson,
Chem. Soc. Rev., 2009, 38, 391; G. Jaouen,
Bioorganometallics: Biomolecules, Labeling, Medicine, Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim, 2006.
91 M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger and
B. K. Keppler, Dalton Trans., 2008, 183.
92 J. A. Ocheskey, S. E. Harpstrite, A. Oksman, D. E. Goldberg
and V. Sharma, Chem. Commun., 2005, 12, 1622.
93 C. Biot, G. Glorian, L. A. Maciejewski, J. S. Brocard,
O. Domarle, G. Blampain, P. Millet, A. J. Georges,
H. Abessolo, D. Dive and J. Lebibi, J. Med. Chem., 1997,
40, 3715.
94 N. Chavain, E. Davioud-Charvet, X. Trivelli, L. Mbeki,
M. Rottmann, R. Brun and C. Biot, Bioorg. Med. Chem.,
2009, 17, 8048.
95 R. Arancibia, F. Dubar, B. Pradines, I. Forfar, D. Dive,
A. H. Klahn and C. Biot, Bioorg. Med. Chem., 2010, 18, 8085.
96 P. F. Salas, C. Herrmann, J. F. Cawthray, C. Nimphius,
A. Kenkel, J. Chen, C. de Kock, P. J. Smith, B. O. Patrick,
M. J. Adam and C. Orvig, J. Med. Chem., 2013, 56, 1596.
97 C. Herrmann, P. F. Salas, J. F. Cawthray, C. de Kock,
B. O. Patrick, P. J. Smith, M. J. Adam and C. Orvig,
Organometallics, 2012, 31, 5736.
98 F. Bellot, F. Cosledan, L. Vendier, J. Brocard, B. Menunier
and A. Robert, J. Med. Chem., 2010, 53, 4103.
99 L. Glans, D. Taylor, C. de Kock, P. J. Smith, M. Haukka,
J. R. Moss and E. Nordlander, J. Inorg. Biochem., 2011,
105, 985.
100 S. D. Khanye, J. Gut, P. J. Rosenthal, K. Chibale and
G. S. Smith, J. Organomet. Chem., 2011, 696, 3296.
101 L. Glans, W. Hu, C. Jost, C. de Kock, P. J. Smith, M. Haukka,
H. Bruhn, U. Schatzschneider and E. Nordlander, Dalton
Trans., 2012, 41, 6443.
102 Y. Li, C. de Kock, P. J. Smith, K. Chibale and G. S. Smith,
Organometallics, 2014, 33, 4345.
103 K. Kumar, S. Schniper, A. G. Alez-Sarr´ıas, A. A. Holder,
N. Sanders, D. Sullivan, W. L. Jarrett, K. Davis, F. Bai,
N. P. Seeram and V. Kumar, Eur. J. Med. Chem., 2014, 86, 81.
104 D. De, F. M. Krogstad, L. D. Byers and D. J. Krogstad, J. Med.
Chem., 1998, 41, 4918.
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 82676–82698 | 82697
Review RSC Advances
Pu
bl
ish
ed
 o
n 
11
 S
ep
te
m
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/3
0/
20
20
 3
:1
6:
12
 A
M
. 
View Article Online
105 T. S. Feng, E. M. Guantai, M. J. Nell, C. E. J. van Rensburg,
H. C. Hoppe and K. Chibale, Bioorg. Med. Chem. Lett., 2011,
21, 2882.
106 M. C. Lombard, D. D. N'Da, J. C. Breytenbach, P. J. Smith
and C. A. Lategan, Bioorg. Med. Chem. Lett., 2010, 20, 6975.
107 M. C. Lombard, D. D. N'Da, J. C. Breytenbach, P. J. Smith
and C. A. Lategan, Bioorg. Med. Chem. Lett., 2011, 21, 1683.
108 T. S. Feng, E. M. Guantai, M. J. Nell, E. J. Constance,
V. Rensburg, K. Ncokazi, T. J. Egan, H. C. Hoppe and
K. Chibale, Biochem. Pharmacol., 2011, 82, 236.
109 F. Cosle´dan, L. Fraisse, A. Pellet, F. Guillou, B. Mordmu¨ller,
P. G. Kremsner, A. Moreno, D. Mazier, J. P. Maffrand and
B. Meunier, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 17579.
110 N. C. P. Arau´jo, V. Barton, M. Jones, P. A. Stocks, S. A. Ward,
J. Davies, P. G. Bray, A. E. Shone, M. L. S. Cristiano and
P. M. O'Neill, Bioorg. Med. Chem. Lett., 2009, 19, 2038.
111 L. Gupta, K. Srivastava, S. Singh, S. K. Puri and
P. M. S. Chauhan, Bioorg. Med. Chem. Lett., 2008, 18, 3306.
112 V. K. Zishiri, M. C. Joshi, R. Hunter, K. Chibale, P. J. Smith,
R. L. Summers, R. E. Martin and T. J. Egan, J. Med. Chem.,
2011, 54, 6956.
113 F. Kobarfard, V. Yardley, S. Little, F. Daryaee and
K. Chibale, Chem. Biol. Drug Des., 2012, 79, 326.
114 A. Kumar, K. Srivastava, S. R. Kumar, S. K. Puri and
P. M. S. Chauhan, Bioorg. Med. Chem. Lett., 2010, 20, 7059.
115 C. C. Musonda, G. A. Whitlock, M. J. Witty, R. Brun and
M. Kaiser, Bioorg. Med. Chem. Lett., 2009, 19, 481.
116 C. J. A. Ribeiro, S. P. Kumar, J. Gut, L. M. Gonçalves,
P. J. Rosenthal, R. Moreira and M. M. M. Santos, Eur. J.
Med. Chem., 2013, 69, 365.
117 K. Ersmark, B. Samuelsson and A. Hallberg, Med. Res. Rev.,
2006, 26, 626.
118 N. Vaiana, M. Marzahn, S. Parapini, P. Liu, M. Dell'Agli,
A. Pancotti, E. Sangiovanni, N. Basilico, E. Bosisio,
B. M. Dunn, D. Taramelli and S. Romeo, Bioorg. Med.
Chem. Lett., 2012, 22, 5915.
119 M. Mungthin, P. G. Bray, R. G. Ridley and S. A. Ward,
Antimicrob. Agents Chemother., 1998, 42, 2973.
120 W. A. Andayi, T. J. Egan, J. Gut, P. J. Rosenthal and
K. Chibale, ACS Med. Chem. Lett., 2013, 4, 642.
121 L. van Heerden, J. C. Breytenbach, C. de Kock, P. J. Smith,
J. W. Breytenbach, T. T. Cloete and D. D. N'Da, Eur. J.
Med. Chem., 2012, 55, 335.
122 M. N. Aminake, A. Mahajan, V. Kumar, R. Hans, L. Wiesner,
D. Taylor, C. de Kock, A. Grobler, P. J. Smith, M. Kirschner,
A. Rethwilm, G. Pradel and K. Chibale, Bioorg. Med. Chem.,
2012, 20, 5277.
123 A. Parthiban, J. Muthukumaran, A. Manhas, K. Srivastava,
R. Krishna and H. S. P. Rao, Bioorg. Med. Chem. Lett.,
2015, DOI: 10.1016/j.bmcl.2015.08.030.
124 D. S. B. Ongarora, N. Strydom, K. Wicht, M. Njoroge,
L. Wiesner, T. J. Egan, S. Wittlin, U. Jurva,
C. M. Masimirembwa and K. Chibale, Bioorg. Med. Chem.,
2015, 23, 5419.
125 A. H. Romero, M. E. Acosta, N. Gamboa, J. E. Charris,
J. Salazar and S. E. Lopez, Bioorg. Med. Chem., 2015, 23,
4755.
82698 | RSC Adv., 2015, 5, 82676–82698 This journal is © The Royal Society of Chemistry 2015
RSC Advances Review
Pu
bl
ish
ed
 o
n 
11
 S
ep
te
m
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 6
/3
0/
20
20
 3
:1
6:
12
 A
M
. 
View Article Online
